Intra-Cellular Therapies Stock Discussion

Ready for some research results?
Summary: XTNT is really undervalued and oversold. Also, ITCI, I guess. Not LLY though, fuck them.

Intra-Cellular Therapies is nearing breakeven, contingent on maintaining a 57% annual growth rate. Its lack of debt, unusual for a pharma company, reduces investment risk.

The market seems optimistic about Intra-Cellular Therapies, Inc. given its strong revenue growth and share price momentum. It's recommended to take a closer look at this stock.

Recent insider selling at Intra-Cellular Therapies, especially by Mark Neumann, could negatively impact the stock. Despite high insider ownership, the absence of insider purchases over the past year suggests insiders don't see the shares as a bargain.

Intra-Cellular Therapies' high P/S ratio may signal investor hope for strong revenue, though analysts show less confidence. Their high valuation could face significant risk due to the disparity between the P/S ratio and revenue predictions.

The substantial ownership of Intra-Cellular Therapies' shares by insiders hints at alignment with shareholders, but the absence of recent insider buying and significant insider selling in the past year could mar confidence. Analyst forecasts might offer a clearer view on the investment.